Member Info for Chazzy2

https://www.youtube.com/embed/U4UGZPgDavM?autoplay=1 FFWD presentation and others from the show now on the MI website.

It's not a gimmick, just good business practise in order to get customers on board. Of course it will take a while for the word to get out there but things can move quickly via social media once they start. I think the real turning point will be when major publishers e.g newspapers adopt the system as a means of payment. Others will follow and there will be very quick adoption after that. Getting the publishers and other content providers on board will be more important than finding wallet holders in the long run.

I thought Ed and Antonio gave very good presentations at the MI show for FFWD and Nuu respectively. The panel discussion including Antonio about the global future of cannabis and the regulations was interesting also. The videos will be out soon on so should be able to catch up if you missed it. It was a shame SALV weren't exhibiting or presenting this year. I would have liked to have had a chat with some of the board.

FFWD and Nuuvera exhibiting at Master Investor show next Sat. Great opportunity to get your questions answered.

Great update. All progressing well.

https://www.investegate.co.uk/fastforward-inn-ltd--ffwd-/rns/investee-company-update--intensity-therapeutics/201802271543521310G/

Presentation available on advfn.

With today's news announcement that prostate cancer has overtaken breast cancer as Britain's third most common cancer, there is a need for a quick and simple diagnostic test for prostate cancer other than the unreliable current gold standard PSA blood test, followed by a highly invasive biopsy. So what better time is there to raise the awareness of the Parsortix test, with its very high sensitivity in predicting prostate (amongst others) cancer and 100% specificity, compared to the large number of false positives that the PSA test delivers.

up 12% currently and rising...!

http://www.nuuvera.com/assets/media/nuuvera-pr-tersum.pdf

The BBC report about the liquid biopsy test and its usefulness in detecting cancer is really underpinning how important blood tests will be in the future in diagnosing cancer, Whilst the test results are encouraging, the 40% sensitivity is detecting cancer in the early stages shows that there is still a long way to go in achieving a meaningful test. The report describes cTDNA techniques which have been around for some time now and which have limitations compared to the Parsortix type CTC systems, That is where Angle really has the edge. Its technology is proven, it has high sensitivity in detecting cancer at the early stages and and it can capture live intact tumour cells which can be used in personalised medicine also. What would be really interesting now is a head to head comparison of the sensitivity of the cTDNA system and the Parsortix system in the diagnosis of early stage different cancer types. I feel the results would once and for all reveal how superior the CTC system is, of which Angle is probably the leading player in the world.

http://www.courant.com/business/hc-biz-westport-cancer-therapy-20171222-story.html

https://westfaironline.com/96772/westports-intensity-therapeutics-gains-ground-with-potential-game-changing-cancer-treatment/

Disappointing to see the sp drop so much in recent days. There does not appear to be any fundamental reason for it. Maybe investors are freeing up cash for more near-term opportunities. Who knows. Still a long term fantastic buy in my opinion, and now even cheaper to buy. Anyone else out there.......? This feels like the Marie Celeste at times!

The following has been copied and pasted from the RNS of FFWD, which also has a stake in Intensity. Very encouraging news. In Q3 2017 one new patient participated in Intensity's on-going trial. There have been no dose limiting side effects to date. Preliminary indication is that the patient's injected tumor shrank. Intensity has reported to shareholders that this preliminary tumor regression finding is encouraging. The regulatory agencies mandated treatment at a low drug dose, low concentration (within the tumor) and minimal dosing frequency.

Hi Steelstones, this is one I've been following for about five years now, and you've come in at a good time, just as the feasibilty study is being completed, permits granted and the nickel price rising steadily. The fortunes of HZM are heavily geared towards the nickel price, but HZM will be one of the lowest cost nickel saprolite producers. Excellent management with Jeremy Martin. (listen to his interviews as he always sounds very professional and inspiring). On production this could possibly 10 bag, that is if it isn't taken out by then by one of the majors for a substantial price beforehand. One of the best mining shares on AIM in my opinion at the moment.

No clinical trial results until next year but there may well be updates on how the trial is progressing.

Good to see SALV adding to its portfolio of investments. Hopefully news on Intensity soon.

Hi, yes I'm watching this one too. Potential for huge upside over the next couple of years but you just have to be patient. The management are the best in their field in cancer immunotherapy. Clinical trials and proof of concept take time and for commercial sensitivity reasons the company cannot report on clinical trial progress, but there is plenty going on for sure.

It's the same old AIM story of buy on the build-up to news and sell on the news itself. Best thing is to forget about the sp and just look at the unfolding story. AGL with its Parsortix system is building up to becoming a global leader in the rapidly growing field of liquid biopsy. After FDA approval within the next 1-2 years I can see AGL being a likely candidate for a buy-out by one of the big medtech companies. It's worth waiting for imho despite the frustratingly slow pace. Yesterdays news, although rather underwhelming in the shareholder response, was another significant milestone, and will be noticed. As with all things medical, things move incredibly slowly though. One consolation is that any competitor will have to overcome the same rigourous hurdles. AGL however has a huge head start and is still on track to become the first FDA approved system for harvesting CTC's for analysis. Patience needed here.